. To decide between these models it will be important to determine whether TLR9 or DNA-PK mediate specific sequence recognition of CpG-DNA.
The effects of null mutations in mice always need to be interpreted with caution, and it remains possible that neither of these molecules is the specific CpG-DNA receptor. There is no obvious structural basis for the recognition of DNA by the extracellular or intracellular domains of TLR9, and no evidence is presented by Hemmi Although the SCID is not a complete null mutation of DNA damage, had no effect on the response to immuno-DNA-PK, it clearly has a powerful phenotypic effect. stimulatory DNA.
Recent studies have confirmed that the C-terminal doMechanisms by which TLR9 and DNA-PK main of DNA-PKcs, which is missing in the SCID mouse, Might Interact is actually needed for catalytic activity (Beamish et al., It is intriguing that two groups simultaneously present 2000), implying that the kinase activity of DNA-PKcs data implicating two apparently unlinked biological may not be required for CpG induced signaling. A resolupathways in CpG-DNA detection (Figure 1) . A number tion of the difference in phenotype between the SCID, of possible models could explain the data, although no and the DNA-PKcs knockout, may give an insight into single one of these models presently is favored. First, the precise role of this gene product. it is possible that DNA-PK and TLR9 provide parallel An additional element that needs to be reconciled signals that are both required for innate immune activawith the models described above is the requirement for tion. In this model both pathways lead to NFB activation endocytosis in the CpG-DNA response; obviously this as described in Figure 1 . The weakness of this model adds considerable complexity. Since we do not yet know is that the TLR9 pathway is derived by analogy with the the localization of TLR9, it is possible that ligand must TLR4 pathway, and that DNA-PK is not required for be delivered to the receptor via an acidified endocytic activation of NFB by TLR4 (as implied by the lack of compartment. Alternatively, endocytosis may be reany effect of the mutation of the enzyme on the response quired for TLR9 signaling. Finally, if DNA-PK is the recepof macrophages to LPS). However, since we have an tor for CpG-DNA, its localization within the nucleus and incomplete understanding of the TLR4 pathway, it is cytoplasm would require delivery of the ligand to the possible that DNA-PK serves a function in TLR9 signalcytoplasm, a process that might require prior endocytoing that is analogous to an, as yet, undefined component sis (Figure 1) . Clearly, much remains to be learned about in the TLR4 pathway. This suggests a second model this important pathway. where TLR9 and DNA-PK are sequentially activated in Other questions also come to mind. The deletion of a linear signaling pathway (Figure 2 ). In this model TLR9 either DNA-PK or TLR9 might have additional consecould mediate the recognition of CpG-DNA, and DNAquences that may indirectly affect the CpG-DNA recog-PK could be part of its downstream signaling pathway. nition pathway. For example, DNA-PK has a central role Alternatively, DNA-PK could mediate CpG-DNA recogniin the generation of immunoglobulin and T cell receptor tion and activate a downstream signaling pathway that rearrangements, and given the known interactions berequires TLR9. For example, DNA-PK could stimulate tween innate and adaptive immunity, indirect regulation the production of a secreted TLR9 ligand that functions of the CpG-DNA response might also occur. Additionally, the innate response to CpG-DNA is restricted to in an autocrine manner. This would be analogous to Toll host immune cells, whereas DNA-PK has a much wider distribution. Regardless of these questions, there is no doubt that the very important contributions by the groups of Akira and Raz represent a big boost to the study of the actions of foreign DNA and will generate new avenues to identify immunomodulators that mimic the actions of foreign DNA, but are more bioavailable.
